Last updated: June 5, 2026

Back to directory

Anumana ECG-AI medical AI product profile

Cardiovascular AI platform using standard 12-lead ECGs to surface signals such as low ejection fraction, pulmonary hypertension, and cardiac amyloidosis for clinician follow-up.

Screenshot of the official Anumana ECG-AI product page
Precision medicine and data

Best fit

Health systems evaluating FDA-cleared cardiac detection support that can fit existing ECG, EHR, and cardiology referral workflows.

Primary use case
FDA-cleared ECG-AI algorithms for identifying cardiovascular risk signals from standard 12-lead ECG workflows
Audience
Cardiology, primary care, emergency medicine, health-system innovation, ECG management, and clinical informatics teams
Risk level
High
Pricing signal
Enterprise and health-system pricing; request current algorithm, integration, reimbursement, and regional availability terms.
Official sources
6 official sources

Compare within workflow: Precision medicine and data · comparison shortlist · source index

Regulatory, privacy, evidence, and workflow lens

Product-specific review. These product-specific signals summarize what the cited sources imply before treating Anumana ECG-AI as safe for a local clinical, operational, or research workflow.

Regulatory / FDAMatch each deployment to the exact cleared algorithm and intended use, including K232699 for low ejection fraction and K252360 for pulmonary hypertension; do not generalize clearance across future or investigational cardiac conditions.
PrivacyReview ECG, EHR, result-routing, audit-log, customer-support, and integration data flows; Anumana says the pulmonary hypertension algorithm runs within the health-system environment, but contract and architecture review still matter.
EvidenceEvaluate local performance by ECG source, patient mix, prevalence, care setting, downstream echo or referral pathway, false-positive burden, and whether published sensitivity and specificity match the intended workflow.
WorkflowBest governed as clinician-reviewed cardiac detection support with defined ECG-system integration, result display, referral criteria, cardiology escalation, monitoring, and patient communication rules.

Where Anumana ECG-AI fits

Anumana describes ECG-AI as a cardiology AI platform that applies FDA-cleared algorithms to standard 12-lead ECGs; FDA records list cleared Anumana ECG-AI algorithms for low ejection fraction and pulmonary hypertension, and Anumana's materials describe health-system workflow integration and U.S. commercial availability for ECG-AI.

Not for: Standalone diagnosis, therapy selection, use outside cleared indications, or deployment without cardiology, primary-care, ECG-system, and informatics governance.

What to verify before using Anumana ECG-AI

Source links

Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.

Related medical AI products